MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.770
+0.030
+0.80%
After Hours: 3.770 0 0.00% 16:10 01/02 EST
OPEN
3.780
PREV CLOSE
3.740
HIGH
3.830
LOW
3.700
VOLUME
108.29K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.000
MARKET CAP
179.48M
P/E (TTM)
-1.3439
1D
5D
1M
3M
1Y
5Y
1D
SAB Biotherapeutics files $300M mixed securities shelf
TipRanks · 12/30/2025 15:15
SAB Biotherapeutics Announces Offering Up To $300M Of Securities; At The Market Offering Up To $75M Of Common Stock
Benzinga · 12/30/2025 15:13
SAB BIOTHERAPEUTICS INC - AT THE MARKET OFFERING UP TO $75 MLN OF COMMON STOCK - SEC FILING
Reuters · 12/30/2025 15:10
SAB Biotherapeutics Launches New $75 Million ATM Program
TipRanks · 12/29/2025 21:39
SAB Biotherapeutics Enters Sales Agreement With UBS Securities; Co May Offer And Sell From Time To Time Common Stock Of Up To $75M
Benzinga · 12/29/2025 21:12
SAB BIOTHERAPEUTICS INC - ENTERS SALES AGREEMENT WITH UBS SECURITIES - SEC FILING
Reuters · 12/29/2025 21:01
SAB BIOTHERAPEUTICS INC - CO MAY OFFER AND SELL FROM TIME TO TIME COMMON STOCK OF UP TO $75 MLN - SEC FILING
Reuters · 12/29/2025 21:01
Weekly Report: what happened at SABS last week (1222-1226)?
Weekly Report · 12/29/2025 09:49
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.